Form 4: Cullinan Therapeutics Director Thomas Ebeling Exercises Stock Options and Disposes of Shares

Director Thomas Ebeling exercised stock options and disposed of 18,450 shares of Cullinan Therapeutics (CGEM) on June 10, 2024.

Summary

• On June 10, 2024, Thomas Ebeling, a director of Cullinan Therapeutics, Inc. (CGEM), executed a transaction involving the company's stock.
• Ebeling exercised stock options to acquire 18,450 shares of Common Stock at a price of $13 per share.
• Simultaneously, Ebeling disposed of 18,450 shares.
• Following these transactions, Ebeling directly owns 186,653 shares of Cullinan Therapeutics.
• The exercised stock options were originally granted on June 8, 2024, and are set to expire on June 7, 2033.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a director's stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider transactions, which can be closely watched by investors for signals about the company's prospects.

Stakeholder Impact

• Shareholders may be interested in this transaction as it provides insight into the actions of a company director.

Key Dates